コンテンツへスキップ
Merck

OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination.

EMBO molecular medicine (2016-02-18)
Maria Francesca Baietti, Michal Simicek, Layka Abbasi Asbagh, Enrico Radaelli, Sam Lievens, Jonathan Crowther, Mikhail Steklov, Vasily N Aushev, David Martínez García, Jan Tavernier, Anna A Sablina
要旨

Activation of the RAS oncogenic pathway, frequently ensuing from mutations in RAS genes, is a common event in human cancer. Recent reports demonstrate that reversible ubiquitination of RAS GTPases dramatically affects their activity, suggesting that enzymes involved in regulating RAS ubiquitination may contribute to malignant transformation. Here, we identified the de-ubiquitinase OTUB1 as a negative regulator of RAS mono- and di-ubiquitination. OTUB1 inhibits RAS ubiquitination independently of its catalytic activity resulting in sequestration of RAS on the plasma membrane. OTUB1 promotes RAS activation and tumorigenesis in wild-type RAS cells. An increase of OTUB1 expression is commonly observed in non-small-cell lung carcinomas harboring wild-type KRAS and is associated with increased levels of ERK1/2 phosphorylation, high Ki67 score, and poorer patient survival. Our results strongly indicate that dysregulation of RAS ubiquitination represents an alternative mechanism of RAS activation during lung cancer development.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
抗OTUB1抗体 ウサギ宿主抗体, affinity isolated antibody, buffered aqueous glycerol solution